Biography

• Professor of Dept. of respiratory medicine, Shanghai Chest Hospital; Vice-president of Shanghai Chest Hospital; Chief of Pulmonary Dept. of Shanghai Chest Hospital; Shanghai City Leading Talent; the State Council special allowance experts; Chief of Clinic trails centre of Shanghai Chest hospital, Shanghai, China

• Dr. Han specializes in lung cancer biological immune targeted therapy and clinical study of new antitumor drugs. As a PI or participant, He participated in the international multi-center subject of the IPASS, the EAP, INTEREST, INFORM, S012, MOK-806, IGNITE, LEAP007,  ALTER 0303，BEYONG,JO41492 and other 57 clinical trials, the quantity and quality of its enrolled among the domestic frontier evaluation results in a recent survey of the most influential international multi-center the IPASS clinical research, I enrolled in a single center, the largest number of clinical research patients in The world. Dr Han is a leading PI of third-line drug—Anlotinib(multi-target anti-angiogenesis TKI) for non-small cell lung cancer in China. Dr Han is also a leading PI for many international multicenter clinical studies, such as IGNITE, LEAP 007,JO41492, MO29872,BPI-2358-103 et al. As PI, Dr Han led the clinical research of bevacizumab-the first biological analogue in China.

• Dr Han is also the recipient of several awards including “The eighth Chinese respiratory physicians Award ” in 2013 ,“China Medical Science and Technology Award” in 2014, “Shanghai medical science Award” for several times.

• Dr. Han is a committee member of numerous associations and societies including executive member of CSCO, the chairman of Chinese medical biological immunology society tumor branch, vice president of Shanghai Cancer Society, vice chairman of Shanghai Medical Association of tumor target molecule.